Screener
Axsome Therapeutics AXSM Q3 2026 earnings
Reported November 2, 2026 · Before market open
Revenue$259.7MBeat by $10.5M
EPS-$0.25Beat by $0.38
Revenue estimate$249.2M
EPS estimate-$0.63
“Axsome delivered 52% year-over-year total revenue growth in the third quarter, surpassing a one-billion-dollar annual run rate. We expect sustained momentum driven by strong underlying demand for Auvelity in major depressive disorder, and continued acceleration of new patient initiations in Alzheimer's disease agitation. Our industry-leading neuroscience pipeline continued to advance, leading to multiple anticipated regulatory and clinical trial milestones in the coming quarters. Our commercial and research and development performance positions us to continue to deliver innovation targeting significant unmet needs in brain health, with the potential to improve the lives of millions of patients.”
Next report
Nov 2, 2026 (Today)Revenue estimate$249.2M
EPS estimate-$0.63
Versus estimates
Revenue
FAQ
- When did Axsome Therapeutics report Q3 2026 earnings?
- Axsome Therapeutics (AXSM) reported Q3 2026 earnings on November 2, 2026 before market open.
- What were Axsome Therapeutics's Q3 2026 revenue and EPS?
- Axsome Therapeutics reported revenue of $259.7M and eps of $-0.25 for Q3 2026.
- Did Axsome Therapeutics beat estimates in Q3 2026?
- Revenue beat the consensus estimate of $249.2M by $10.5M. EPS beat the consensus estimate of $-0.63 by $0.38.
- How did Axsome Therapeutics's Q3 2026 results compare year-over-year?
- Compared to the same quarter a year prior, revenue grew 51.9% from $171.0M a year earlier and eps grew 73.4% from $-0.94.
- Where can I find Axsome Therapeutics's Q3 2026 SEC filings?
- You can read the 8-K earnings release (0001193125-26-442628) directly on SEC EDGAR. The filing index links above go to sec.gov.
